# Study of LW402 in Moderate-to-Severe Atopic Dermatitis

> **NCT07186387** · PHASE2 · COMPLETED · sponsor: **Shanghai Longwood Biopharmaceuticals Co., Ltd.** · enrollment: 144 (actual)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** LW402
- **DRUG:** LW402 placebo

## Key facts

- **NCT ID:** NCT07186387
- **Lead sponsor:** Shanghai Longwood Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-11
- **Primary completion:** 2024-09-25
- **Final completion:** 2025-02-13
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07186387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07186387, "Study of LW402 in Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07186387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*